Dr Michael Rosenblatt joins Merck & Co
This article was originally published in Scrip
Executive Summary
Dr Michael Rosenblatt has been named executive vice-president and chief medical officer at Merck & Co. He will report directly to Merck's chairman, president and CEO, Richard Clark, will serve on the company’s executive committee and will oversee the company's global centre for scientific affairs. Dr Rosenblatt has served as dean of Tufts University School of Medicine since 2003. Before that, he was George R Minot Professor of Medicine at Harvard Medical School and chief of the division of bone and mineral metabolism research at Beth Israel Deaconess Medical Center.
You may also be interested in...
Flagship Ventures Tempts Former Merck CMO With 'Creative' Mentoring Role
Flagship Ventures has recruited former Merck Chief Medical Officer Michael Rosenblatt as its CMO to mentor biopharma startups in the venture firm's portfolio – a hire that appears to be the first of its kind.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.